• Aktuelle Seite:  
  • Home
  • Naltrexon
A- A A+

Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial

Samet, Jeffrey H et al.

The Lancet HIV, Volume 10, Issue 9, e578 - e587 

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00143-1/fulltext

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence. 

Li X, Langleben DD, Lynch KG, Wang GJ, Elman I, Wiers CE, Shi Z. 

Front Psychiatry. 2023 Aug 2;14:1247961. doi: 10.3389/fpsyt.2023.1247961. PMID: 37599869; PMCID: PMC10433165.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433165/

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone. 

Marciuch A, Birkeland B, Benth JŠ, Solli KK, Tanum L, Mathisen I, Weimand B. 

Heliyon. 2023 Jul 5;9(7):e17516. doi: 10.1016/j.heliyon.2023.e17516. PMID: 37449176; PMCID: PMC10336734.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336734/

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. 

Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. 

J Clin Psychol. 2023 Aug 16. doi: 10.1002/jclp.23582. Epub ahead of print. PMID: 37584532.

https://onlinelibrary.wiley.com/doi/10.1002/jclp.23582

Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. 

Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD. 

J Clin Psychiatry. 2023 Apr 17;84(3):22br14567. doi: 10.4088/JCP.22br14567. PMID: 37074295; PMCID: PMC10119768.

https://www.psychiatrist.com/jcp/addiction/depression-cue-reactivity-in-opioid-use-disorder-during-naltrexone-xr-treatment/

Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. 

Spreer M, Grählert X, Klut IM, Al Hamdan F, Sommer WH, Plawecki MH, O'Connor S, Böttcher M, Sauer C, Smolka MN, Zimmermann US. 

Transl Psychiatry. 2023 Apr 5;13(1):113. doi: 10.1038/s41398-023-02404-7. PMID: 37019884; PMCID: PMC10076427.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076427/

Shifting the Sociometer: Opioid Receptor Blockade Lowers Self-Esteem. 

Tchalova K, Beland S, Chanda ML, Levitin DJ, Bartz JA. 

Soc Cogn Affect Neurosci. 2023 Mar 24:nsad017. doi: 10.1093/scan/nsad017. Epub ahead of print. PMID: 36961732.

https://academic.oup.com/scan/advance-article/doi/10.1093/scan/nsad017/7085663

The effects of naltrexone on retention in treatment and being opioid-free in opioid-dependent people: A systematic review and meta-analysis. 

Zangiabadian M, Golmohammadi S, Nejadghaderi SA, Zahmatkesh MM, Nasiri MJ, Sadeghian M. 

Front Psychiatry. 2022 Sep 26;13:1003257. doi: 10.3389/fpsyt.2022.1003257. PMID: 36226100; PMCID: PMC9548642.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548642/

Naltrexone: Addiction Drug Shows Promise Lifting Long COVID Brain Fog, Fatigue

(Medscape, USA, 18.10.2022)

https://www.medscape.com/viewarticle/982604#vp_2

Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. 

Pitt B, Tate AM, Gluck D, Rosenson RS, Goonewardena SN. 

Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):402-405. doi: 10.1093/ehjcvp/pvac014. PMID: 35179184; PMCID: PMC8903502.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903502/

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone. 

Karlsson AT, Vederhus JK, Clausen T, Weimand B, Solli KK, Tanum L. 

Int J Environ Res Public Health. 2022 Sep 11;19(18):11435. doi: 10.3390/ijerph191811435. PMID: 36141709; PMCID: PMC9517108.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517108/

Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses. 

Bello M. 

Molecules. 2022 Aug 2;27(15):4919. doi: 10.3390/molecules27154919. PMID: 35956868; PMCID: PMC9369988.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369988/

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study. 

Marciuch, A., Brenna, I.H., Weimand, B. et al.

Addict Sci Clin Pract 17, 36 (2022). doi.org/10.1186/s13722-022-00317-2

https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-022-00317-2

Treatment Choices: Naltrexone

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P804.pdf

Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study. 

Rahimi M, Kargar A, Hazegh Fetratjoo D, Hosseini SM, Mahdavinejad A, Shadnia S. 

Arch Acad Emerg Med. 2022 May 1;10(1):e34. doi: 10.22037/aaem.v10i1.1554. PMID: 35765606; PMCID: PMC9187130.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187130/

HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. 

Korthuis, PT, Cook, RR, Lum, PJ, Waddell, EN, Tookes, H, Vergara-Rodriguez, P, et al. 

Addiction. 2022; 117: 1961– 1971. doi.org/10.1111/add.15836

https://onlinelibrary.wiley.com/doi/10.1111/add.15836

Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. 

Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A. 

Drug Alcohol Depend. 2022 Apr 1;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub 2022 Feb 2. PMID: 35131528; PMCID: PMC8957614.

https://www.sciencedirect.com/science/article/pii/S0376871622000801

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. 

Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sullivan MA, Bloomgren G. 

Drug Saf. 2021 Mar;44(3):351-359. doi: 10.1007/s40264-020-01020-4. Epub 2020 Nov 30. PMID: 33258068; PMCID: PMC7892734.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892734/

Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment. 

Biondi BE, Frank CA, Forray A, Springer SA. 

Subst Abus. 2021;42(4):905-911. doi: 10.1080/08897077.2021.1900984. Epub 2021 Mar 22. PMID: 33750285; PMCID: PMC8455717.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455717/

Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. 

Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A. 

Drug Alcohol Depend. 2022 Feb 2;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub ahead of print. PMID: 35131528.

https://www.sciencedirect.com/science/article/pii/S0376871622000801

Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. 

Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. 

J Subst Abuse Treat. 2019 Sep;104:34-41. doi: 10.1016/j.jsat.2019.05.008. Epub 2019 May 10. PMID: 31370983; PMCID: PMC8215516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215516/

Naltrexone Implant for Opioid Use Disorder. 

Edinoff AN, Nix CA, Orellana CV, StPierre SM, Crane EA, Bulloch BT, Cornett EM, Kozinn RL, Kaye AM, Murnane KS, Kaye AD. 

Neurol Int. 2021 Dec 30;14(1):49-61. doi: 10.3390/neurolint14010004. PMID: 35076607; PMCID: PMC8788412.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788412/

'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. 

Brenna IH, Marciuch A, Birkeland B, Veseth M, Røstad B, Løberg EM, Solli KK, Tanum L, Weimand B. 

J Subst Abuse Treat. 2021 Nov 27:108667. doi: 10.1016/j.jsat.2021.108667. Epub ahead of print. PMID: 34865937.

https://linkinghub.elsevier.com/retrieve/pii/S0740-5472(21)00393-7

Opioid antagonism modulates wanting-related frontostriatal connectivity. 

Soutschek A, Weber SC, Kahnt T, Quednow BB, Tobler PN. 

Elife. 2021 Nov 11;10:e71077. doi: 10.7554/eLife.71077. PMID: 34761749; PMCID: PMC8598157.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598157/

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. 

Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT. 

Addict Sci Clin Pract. 2021 Nov 10;16(1):67. doi: 10.1186/s13722-021-00277-z. PMID: 34758887; PMCID: PMC8579672.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579672/

Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up

Gaulen, Zhanna et al.

Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108656 

https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(21)00382-2/fulltext

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 

Roache, J.D., Pavlicova, M., Campbell, A., Choo, T.-H., Peavy, M., Kermack, A.S., Nunes, E.V., Jr. and Rotrosen, J. (2021), 

Alcoholism: Clinical and Experimental Research. Accepted Author Manuscript. doi.org/10.1111/acer.14729

https://onlinelibrary.wiley.com/doi/10.1111/acer.14729

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. 

Karlsson AT, Vederhus JK, Clausen T, Weimand B, Solli KK, Tanum L. 

J Clin Med. 2021 Sep 30;10(19):4558. doi: 10.3390/jcm10194558. PMID: 34640572; PMCID: PMC8509800.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509800/

Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia. 

Shaheed G, Manjooran AP, Reddy AJ, Nawathey N, Habib S, Brahmbhatt H. 

Cureus. 2021 Sep 2;13(9):e17667. doi: 10.7759/cureus.17667. PMID: 34646707; PMCID: PMC8487298.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487298/

The impact of age and genetics on naltrexone biotransformation. 

Stancil SL, Nolte W, Pearce RE, Staggs VS PhD, Leeder JS. 

Drug Metab Dispos. 2021 Nov 2:DMD-AR-2021-000646. doi: 10.1124/dmd.121.000646. Epub ahead of print. PMID: 34728519.

https://dmd.aspetjournals.org/content/early/2021/11/02/dmd.121.000646.long

  1. Adverse drug reactions with naltrexone: Experience from an addiction treatment center. 
  2. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.  (2)
  3. Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder. 
  4. Life threatening opioid withdrawal syndrome due to inadvertent naltrexone administration and lifesaving result by clonidine. 
  5. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial